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Bile acids (BA) are signaling molecules with a wide range of biological effects, also 33 
identified amongst the most responsive plasma metabolites in the post-prandial state. We 34 
here describe this response to different dietary challenges and report on key determinants 35 
linked to its inter-individual variability.  36 
Healthy men and women (N=72, 62 ± 8 years) were enrolled into a 12-week weight loss 37 
intervention. All subjects underwent an oral glucose tolerance test (OGTT) and a mixed 38 
meal tolerance test (MMTT) before and after the intervention. BA were quantified in plasma 39 
by LC-MS/MS combined with whole genome exome sequencing and fecal microbiota 40 
profiling. 41 
Considering the average response of all 72 subjects, no effect of the successful weight loss 42 
intervention was found on plasma BA profiles. Fasting and post-prandial BA profiles 43 
revealed high inter-individual variability and 3 main patterns in post-prandial BA response 44 
were identified using multivariate analysis. Although the women enrolled were 45 
postmenopausal, gender effects in BA response were evident. Exome data revealed the 46 
contribution of preselected genes to the observed inter-individual variability. In particular, a 47 
variant in the SLCO1A2 gene, encoding the small intestinal BA transporter OATP1A2 was 48 
associated with delayed post-prandial BA increases. Fecal microbiota analysis did not 49 
reveal evidence for a significant influence of bacterial diversity and/or composition on 50 
plasma BA profiles.  51 
The analysis of plasma BA profiles in response to two different dietary challenges revealed 52 
a high inter-individual variability, which was mainly determined by genetics and gender of 53 
host with minimal effects of the microbiota. 54 
 55 
New and Noteworthy:  56 
Considering the average response of all 72 subjects, no effect of the successful weight loss 57 
intervention was found on plasma BA profiles. 58 
Despite high inter-individual variability, 3 main patterns in post-prandial BA response were 59 
identified using multivariate analysis. 60 
A variant in the SLCO1A2 gene, encoding the small intestinal BA transporter OATP1A2 61 
was associated with delayed post-prandial BA increases to both the OGTT and MMTT. 62 
 63 





In addition to their role in solubilizing lipids in the intestine, bile acids (BA) are now 67 
recognized as important signaling molecules. They serve as ligands of the farnesoid X 68 
receptor (FXR) expressed in intestine and liver and thus control synthesis and transport of 69 
BA but also modulate expression of other genes(24, 28, 39, 43, 57, 64). After the discovery 70 
of a G protein-coupled receptor (TGR5) for BA(28, 39), acute metabolic effects of BA 71 
received considerable interest. With the expression of TGR5 and FXR in a wide range of 72 
cell types and tissues, BA effects cover immunomodulation, metabolism of adipose tissue 73 
and muscle as well as gastrointestinal hormone secretion (e.g. GLP-1)(27, 28). TGR5 74 
activation by BA was shown to activate deiodinase, increasing the level of active thyroid 75 
hormone which in turn elevates the expression of enzymes involved in fatty acid oxidation 76 
in brown adipose tissue and skeletal muscle(24, 28, 39, 43, 57, 60, 64, 66). TGR5 was also 77 
identified as a target for treatment of obesity and type-2 diabetes. BA can (via farnesoid X 78 
receptor (FXR)-induced activation of short heterodimer partner (SHP) and its effect on 79 
hepatocyte nuclear factor 4 (HNF-4) and/or forkhead box O1 (Foxo1)) decrease the 80 
expression of gluconeogenic enzymes with a beneficial effect on glucose homeostasis in 81 
insulin resistance(28, 35, 38, 39). FXR also participates in the regulation of insulin synthesis 82 
and secretion as well as in the protection of pancreatic islets from lipotoxicity(27, 28, 44, 83 
45). Via SREBP-1c activation, BA were also shown to modulate triacylglycerol synthesis in 84 
rodent liver(61).  85 
Taken the relevance of BA as receptor ligands and their increase in circulation in the post-86 
prandial state, it is remarkable that impressive differences in plasma levels of BA between 87 
individuals are not explained as yet. Within the NutriTech study, we recorded changes in 88 
BA plasma concentrations in 72 healthy male and female (postmenopausal) volunteers in 89 
response to an oral glucose tolerance (OGTT) and a mixed meal tolerance test (MMTT) 90 
combined with exome sequencing and fecal microbiota analysis. We here report on a large 91 
inter-individual variability of plasma BA profiles with pronounced gender effects and the 92 
identification of a number of gene variants underlying hepatic BA synthesis and 93 




1. Study design 96 
The research project NutriTech was funded by the European Union 7 Framework program 97 
(clinicaltrials.gov record: NCT01684917).  It aimed at better phenotyping human volunteers 98 
in response to standardized challenge tests. 72 volunteers (37 women and 35 men) in 99 
average 59.2±4.2 years-old, BMI 29.7±2.7, healthy at the screening considering fasting 100 
glucose and insulin concentrations and blood pressure values were recruited. The subjects 101 
underwent comprehensive phenotyping, including MRI scanning, food intake recording, and 102 
blood profiling for metabolites, hormones and chemokines. All subjects underwent an 103 
OGTT and a MMTT before and after a 12-week period, in which 40 participants followed a 104 
20% caloric restriction diet  while subjects in the control group consumed an average 105 
european diet which was matched for their energy expenditure to maintain body weight. 106 
Challenge tests always started at 09:00 am after 12 hours of fasting. The OGTT drink 107 
consisted of 75g glucose in 250 mL of water consumed within 5 minutes. Blood was 108 
collected in heparin-coated tubes at times 0, 15, 30, 60, 90, 120 and 240 minutes. The 109 
MMTT (also known as the “PhenFlex drink”) was a high-fat, high-glucose, high-caloric drink 110 
(400 ml) consisting of 320 ml tap water, 75g glucose, 60g palm olein, 20g profitar (protein 111 
supplement, Nutricia, Netherlands) and 0,5g artificial vanilla aroma resulting in a shake with 112 
33, 59 and 8% of energy from carbohydrates, lipids and proteins, respectively. The drink 113 
was ingested within 5 minutes and blood was collected at 0, 30, 60, 120, 240, 360 and 480 114 
minutes. Plasma was separated and stored at -80ºC for later analyses. Clinical chemistry 115 
parameters were assayed using enzymatic colorimetric kits and GLP-1 was measured 116 
using an in-house radioimmunoassay as previously described(30).  117 
2. Bile acid analysis 118 
Plasma bile acids were analyzed by a modified method originally described by Tagliacozzi 119 
et al (53). Briefly, 10 µL of plasma were mixed with 10 µL internal standard solution and 500 120 
µL ice-cold methanol was added for deproteinization. Samples were vortexed and 121 
centrifuged at 15.000 g for 10 minutes. The supernatant was transferred to a 96 deep-well 122 
plate and evaporated under a stream of N2. The solid remnants were re-suspended in 123 
methanol:water (1:1). Analysis was performed by LC-MS/MS using a triple quadrupole 124 
mass spectrometer (HPLC Agilent - CA, USA; QTrap 5500 - ABSciex MA, USA). BA were 125 
separated using a gradient with 0.2% formic acid in water and acetonitrile (acetonitrile going 126 
from 30 % at the start of the run to 100 % at 20 minutes) with a flow rate of 0.6 ml/min and 127 
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a reverse phase column (Phenomenex Luna C18(2) 150 x 4,6mm; 5µm particle size), kept 128 
at 40 °C. The mass spectrometer was operated in negative ion mode and mass spectra 129 
were obtained using the multiple reaction-monitoring mode (MRM). Integration of the peaks 130 
was done using Analyst Software (ABSciex MA, USA). Analyte concentration was 131 
calculated using deuterated internal standards (d4-Deoxycholic acid, d4-132 
Glycoursodeoxycholic acid, d4-Glycodeoxycholic acid, d4-Glycocholic acid and d5-133 
Taurocholic acid). Samples were randomized so that every batch contained samples from 134 
men and women, and from OGTT and MMTT performed before and after the intervention to 135 
avoid batch effects. Reference fasting plasma samples (Recipe Clinical Diagnostics 136 
Munich, Germany) were included in each batch and a dilution row of BA standards was 137 
processed in a similar manner in every batch for quantitation purposes. In total, 13 BA were 138 
quantified: ursodeoxycholic acid (UDCA), cholic acid (CA), chenodeoxycholic acid (CDCA), 139 
deoxycholic acid (DCA), glycoursodeoxycholic acid (GUDCA), glycocholic acid (GCA), 140 
glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), 141 
tauroursodeoxycholic acid (TUDCA), taurocholic acid (TCA), taurochenodeoxycholic acid 142 
(TCDCA), taurodeoxycholic aicd (TDCA) and taurolitocholic acid (TLCA). Due to the low 143 
abundancy and values below the lower limit of quantitation, UDCA TUDCA and TLCA were 144 
not taken into consideration in the statistical analysis. In our analyses, BA were grouped as 145 
primary (sum of CA, CDCA, and their taurine and glycine conjugates) or secondary + 146 
tertiary (DCA, LCA, UDCA including taurine and glycine conjugates thereof). The terms 147 
taurine-conjugated, glycine-conjugated, or unconjugated BA are used regardless of whether 148 
BA are primary or secondary + tertiary. In the text, total BA refers to the sum of all individual 149 
BA. 150 
 151 
3. Exome DNA sequencing 152 
Genomic DNA was extracted from saliva, collected using the Oragene® DNA sample 153 
collection kit (DNA Genotek, Ottawa, ON, Canada), following manufacturer's protocol. 154 
Whole-exome sequencing libraries were prepared from DNA using SureSelectXT Human 155 
All Exon V4+UTRs (71Mb) kit (Agilent Technologies, Santa Clara, CA). Sequencing was 156 
performed on a HiSeq25000 platform generating 100 base-pair end reads. After quality 157 
control using FastQC(29) version 0.10.0, sequencing reads were mapped to the GRCh37 158 
(hg19) reference assembly of the human genome using BWA-MEM(36) version 0.7.2.(36) 159 
Variant calling was performed using GATK version 2.6(41) and quality filtered variants were 160 
annotated in ANNOVAR(58). Annotated exonic variants were filtered based on in-silico 161 
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predictive functional effects on the protein by two algorithms incorporated in the ANNOVAR 162 
suite: i) SIFT(31), which relies on the degree of conservation of amino acid residues in 163 
highly conserved regions in sequence alignments derived from closely related sequences 164 
and ii) Polyphen-2(2) which predicts the possible impact of amino acid substitutions on the 165 
stability and function of human proteins using structural and comparative evolutionary 166 
considerations. These approaches indicate a high probability that an amino acid change is 167 
“deleterious” based on a combination of these attributes. The effect of the identified variants 168 
on post-prandial BA metabolism was analyzed by creating allelic gene scores, which 169 
represented the sum of deleterious variants per gene involved in BA synthesis, metabolism 170 
and transport. Where necessary individual variants were analyzed separately. 171 
 172 
4. High-throughput microbiome 16S rRNA gene amplicon sequencing 173 
Fresh stool sample were collected by subjects before and after a 12-week intervention 174 
period. Samples were immediately frozen at −20 °C by the subjects after defecation and 175 
transported in frozen state to the laboratory at TNO where samples were mechanically 176 
homogenized, split into aliquots in sterile 2 ml cryovials and stored at −80 °C. For fecal 177 
genomic DNA isolation, approximately 100-150 mg of fecal material was directly transferred 178 
to DNA isolation plates. Phenol pH8.0 was added and the samples were mechanically 179 
disrupted by bead beating with a 96-well plate Beadbeater (Biospec Products, Bartlesville). 180 
Isolated DNA was extracted and purified with the AGOWA mag Mini DNA Isolation Kit 181 
(AGOWA, LGC genomics, Berlin, Germany) as described in Kelder et al (2014)(29). 182 
Microbiota analysis was performed by high-throughput sequencing of bar-coded amplicons 183 
spanning the archaeal and bacterial V4 hypervariable region. These amplicons, generated 184 
from a standardized quantity of template DNA (100pg) using adapted primers 515F and 185 
806R, were bidirectionally sequenced using the MiSeq system (Illumina, San Diego, CA) as 186 
described previously(11).  187 
Data were analysed as described in detail previously(33). Raw reads were processed using 188 
an in-house developed pipeline (www.imngs.org)(32) based on the UPARSE approach(16). 189 
Sequences were trimmed to the first base with a quality score <3 and then paired. Those 190 
with less than 200 and more than 300 nucleotides and paired reads with an expected error 191 
>3 were excluded from the analysis. Remaining reads were trimmed by five nucleotides on 192 
each end to avoid GC bias and non-random base composition. The presence of chimeras 193 
was tested using UCHIME(15). Operational taxonomic units (OTUs) were clustered at 97% 194 
sequence similarity, and only those with a relative abundance >0.5% in at least one sample 195 
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were kept. Taxonomies were assigned at 80% confidence level using the RDP 196 
classifier(59). 197 
 198 
5. Statistical analysis 199 
Depending on the nature of comparisons, T-test, 1-way ANOVA or 2-way ANOVA with post 200 
hoc multiple comparison Bonferroni’s test were used. Unless otherwise stated, differences 201 
with P<0.05 were considered as significant. Shapiro-Wilk test was used to assess 202 
normality. Results from calculation of area under the curve (AUC), refers to incremental 203 
AUC, which considers individual values at t=0 as baseline. In cases where outliers where 204 
removed, their detection was done using ROUT method. 205 
The contribution of individual predictors to the overall variation of plasma BA concentrations 206 
was quantified by means of percentaged marginal coefficients of determination (R²) which 207 
were obtained by means of ANOVA using a Mixed Design Model taking into account 208 
repeated measures per subject during the MMTT. Individual predictors included allelic gene 209 
scores, microbiota families, gender and MMTT time points. For this analysis, family level 210 
microbiota data were used with a relative abundance of >0.5% in at least 30 % of the 211 
samples. Analysis at lower taxonomic ranks is not compatible with the classification 212 
confidence of short reads and the taxonomic incongruence of some dominant and prevalent 213 
bacterial genera in the human gut.  214 
Statistical analysis of microbiota profiles was performed in the R programming environment 215 
using Rhea (https://lagkouvardos.github.io/Rhea/)(32). OTU tables were normalized to 216 
account for differences in sequence depth. ß-diversity was computed based on generalized 217 
UniFrac distances(12) while α-diversity was assessed on the basis of species richness and 218 
Shannon effective diversity(26). For de novo clustering of microbiota profiles, Partitioning 219 




Effect of the intervention on plasma bile acids 222 
All subjects underwent the OGTT and MMTT challenges two times, separated by 12 weeks 223 
of weight loss intervention. While a subgroup of volunteers (n=32) followed a supervised 224 
diet to keep body weight constant, 40 volunteers followed a diet with a 20% energy 225 
restriction that led to a mean weight loss of 5.6 kg. This weight loss however did not cause 226 
any significant changes in fasting glucose or insulin concentrations (data not shown) nor did 227 
it change the composition and concentrations of circulating BA in fasting state and during 228 
the dietary challenges (Figure 1). Based on the lack of an effect of the weight-loss we 229 
calculated and used the mean values of the BA concentrations during the OGTT and 230 
MMTT. In this way we minimized variation and could overcome problems caused by 231 
eventual missing samples. 232 
Fasting plasma BA levels 233 
Quantification of the most abundant BA species in plasma (collected between 08:00 and 234 
09:00am after 12h of fasting) revealed a high inter-individual variability in both 235 
concentrations as well as composition. For the sum of all BA, a 12-fold difference across 236 
the 72 volunteers was found. Glycine-conjugated BA accounted for around 47% and 237 
taurine-conjugated species for around 7% of the total BA pool, while unconjugated species 238 
represented 46% of total (Figure 2 and Figure 3G and 3H time point 0). Primary BA were 239 
more abundant than the sum of secondary + tertiary and corresponded to approximately 240 
60% of the total BA pool.  241 
Post-prandial responses of plasma BA to OGTT and MMTT 242 
The mean total plasma BA concentration increased 3.3-fold in response to the MMTT 243 
(Figure 3A) with maximal levels reached after 1 hour and remaining constant for up to 6 244 
hours. Even at 8 hours after consumption of MMTT test drink, concentrations were on 245 
average 1.7-fold higher than in overnight fasting state. Bile acid concentrations also 246 
increased during the OGTT but here peak concentrations were reached after 30 minutes 247 
with levels on average 2-fold higher than in fasting state (Figure 3A). After 90 minutes BA 248 
concentrations started to decline to reach fasting state levels after 240 minutes.  249 
Different classes of BA displayed different kinetic behaviors. Based on mean values of all 250 
volunteers, primary BA increased by 3.9-fold during the MMTT and by 2.1-fold during the 251 
OGTT. Secondary + tertiary BA showed a lower response with a maximal increase of 2.8-252 
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fold during the MMTT and 1.8-fold during the OGTT compared to fasting levels (Figures 3B 253 
and 3C). In the OGTT and MMTT, levels of glycine- and taurine-conjugated BA increased 254 
around 5-fold in the MMTT and around 3-fold in the OGTT (Figures 3D and 3E). Plasma 255 
concentration of unconjugated BA showed only a small increase during MMTT (1.6-fold at 256 
240 min) and even a 15% decrease at the end of the OGTT (Figure 3F). A shift in the 257 
composition of circulating BA was observed in the transition from fasting to postprandial 258 
state. Glycine-conjugated BA – comprising 47% of the total BA pool in fasting state - 259 
increased to 68% during the MMTT and the taurine-conjugated species went from 7% to 260 
11%, while unconjugated entities declined from 46% to 20% after 2h in the MMTT (Figure 261 
3H). A very similar change in composition was observed during the OGTT, although in this 262 
case, the increase in glycine-conjugated BA (and concomitant decline in unconjugated 263 
species) was less pronounced (Figure 3G). 264 
Gender-specific differences in post-prandial BA responses  265 
During OGTT, plasma BA concentrations increased similarly in men and women, reaching 266 
maximum values after 30 and 60 minutes, respectively. Women thereafter sustained 267 
maximal concentrations of BA for at least 2 hours, whereas in men concentrations were 268 
significantly reduced already at 90 minutes (P=0.0011) as shown in Figure 4A. The gender-269 
specific differences in response to the OGTT were particularly evident when inspecting the 270 
glycine- and taurine-conjugated BA (P<0.0001 and P=0.0098 for differences in AUC for 271 
taurine- and glycine-conjugated BA, respectively), as demonstrated in Figures 4B and 4C. 272 
Although less pronounced than in the OGTT, gender-related differences were also 273 
observed in response to the MMTT, but only for taurine-conjugated BA (P=0.0085 for 274 
difference in AUC) as shown in Figure 4F. Despite these post-prandial gender differences, 275 
overnight fasting BA concentrations were similar between men and women. 276 
Clusters of post-prandial BA responses 277 
Not only fasting BA concentrations but also post-prandial changes in plasma BA displayed 278 
large inter-individual variability. There was no correlation between the AUC of post-prandial 279 
total BA with their fasting concentration (data not shown). 280 
As compared to an average 3.3-fold increase in circulating total BA levels following the 281 
MMTT, some subjects responded with a more than 10-fold increase, whereas others barely 282 
showed any change. A hierarchical clustering approach based on BA concentration profiles 283 
in response to the MMTT identified 3 subgroups of volunteers with an almost equal 284 
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distribution of men and woman in each cluster. These significant differences in plasma BA 285 
kinetics are shown in Figures 5A and 5B. Different classes of BA displayed distinct kinetic 286 
behaviors, particularly when unconjugated BA were compared to conjugated species. In 287 
cluster 1 (n=35), post-prandial BA concentrations increased on average 4.3-fold with a 288 
maximum reached within the first hour. Even after 8 hours, in this cluster BA concentrations 289 
were 2.3-fold higher than in fasting state. In cluster 3 (n=21), fasting levels of BA were 290 
almost twice as high as in other clusters but here subjects displayed a slower increase in 291 
plasma profiles with maximal values of around 2.9-fold of fasting state after 4 hours, 292 
returning to fasting state concentrations after 8 hours. Subjects in cluster 2 (n=13) 293 
displayed a completely different kinetic profile with plasma concentrations increasing to a 294 
maximum of 4.6-fold of fasting levels at 6 hours, and even after 8 hours levels were still 3.4-295 
fold higher than in fasting state. 296 
Determinants of BA profiles 297 
To identify some of the determinants underlying the different BA kinetics, host genome and 298 
fecal microbiota sequencing approaches were used. Exome sequencing data were 299 
analyzed for genetic heterogeneity in target genes identified by knowledge and GO-300 
classification for a subset of 60 genes involved in hepatic BA synthesis, enterohepatic 301 
recirculation, and transmembrane transport of BA. A list of these genes screened for 302 
variations is provided on Table 1. Subjects were grouped according to the presence of 303 
variants known or predicted to impair protein functionality defined as “deleterious” based on 304 
SIFT and Polyphen-2 algorithms. Although various gene variants revealed associations with 305 
plasma BA profiles (Table 2), those in the SLCO1A2 gene were observed in a number of 306 
volunteers large enough to allow a reliable association with phenotype. SLCO1A2 encodes 307 
the organic anion-transporting polypeptide-1 A2 (OATP1A2), which mediates BA uptake 308 
across the apical membrane of enterocytes in upper small intestine but also in distal 309 
nephrons, cholangiocytes and at the blood brain barrier(10, 21). In this gene, a previously 310 
described functional polymorphism rs11568563 (c.A516C, p.E172D, MAF=0.03) was found 311 
in 9 out of 72 subjects and an additional rare variant rs368672331 (c.G727A, p.G243S) was 312 
found in another subject. All rs11568563 carriers displayed a delayed post-prandial 313 
increase of conjugated BA in plasma compared to the other volunteers not bearing this 314 
variant (Figure 6). Variants in the SLC10A2 gene that encodes the apical sodium-315 
dependent bile acid transporter (ASBT) in ileum (considered the prime site for BA 316 
reabsorption) such as rs71640248, rs117447044 and rs56398830 were also found in 4 317 
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volunteers that as well showed reduced postprandial increases in BA concentrations (data 318 
not shown).  319 
Multivariate analyses providing marginal R² showed that a substantial proportion of the 320 
variation in BA concentration profiles could be attributed to the time point of measurement 321 
during the MMTT, gender, selected SNPs and microbiota (Table 2). Across all individual 322 
parameters, the lowest cumulative values were found for the cholic acid conjugated species 323 
TCA and GCA with 37 and 43% of total variation explained, whereas the highest values 324 
were calculated for DCA and its glycine and taurine-conjugates with 69, 63 and 64% of 325 
variance explained. Up to 50% of total variation could be attributed to the selected SNPs, 326 
particularly in case of DCA and its taurine and glycine conjugates. Variants in the gene 327 
encoding Epoxide hydrolase 1 (EPHX1) were found in 39 subjects and this gene alone 328 
accounted for 14% of variation in DCA concentrations and approximately 30% of variation 329 
in concentrations of its conjugates GDCA and TDCA. Additional individual effects 330 
(particularly for unconjugated primary BA) were found for the canalicular multispecific 331 
organic anion transporter ABCC3, the racemase AMACR that can interconvert BA as well 332 
as for the BA receptor TGR5 encoded by GPBAR1 (variants found in 6 subjects) and for a 333 
putative phospholipid-transporting ATPase encoded by ATP8B1, which displayed 334 
deleterious variants in 26 volunteers. Given the small size of the study population and the 335 
small number of carriers of individual variants no other attempts were made to associate 336 
phenotype and genotypes.  337 
Gender was particularly associated with the concentrations of taurine-conjugated BA. Most 338 
of the selected gut bacterial families had only a marginal effect on BA concentrations, with 339 
the exception of Coriobacteriaceae, Erysipelotrichaceae, and most notably 340 
Peptostreptococcaceae, which accounted for 12% of variation in CA concentrations. 341 
Whereas the family Coriobacteriaceae is known to include bile acid-converting species(46, 342 
62), results pertaining to the Peptostreptococcaceae require additional studies.  343 
To further assess the possible influence of gut microbiota in a non-supervised manner, de 344 
novo clustering of fecal microbial profiles based on phylogenetic distances revealed the 345 
presence of three distinct clusters of individuals (Figure 7). Each of these clusters was 346 
characterized by significant differences in alpha-diversity and in the relative abundance of 347 
specific taxa (data not shown), but supervised multidimensional analysis of BA kinetics 348 
parameters on the basis of these microbiota-derived clusters followed by statistical tests on 349 
individual BA parameters did not reveal any significant associations. Likewise, comparison 350 
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of the fecal microbiota of individuals belonging to the three different BA-specific clusters 351 
(Figure 5) did not show significant differences in any of the bacterial taxonomic groups 352 
identified (data not shown).  353 




The high inter-individual variability of plasma BA levels and composition in the fasting and 356 
post-prandial states found in our study confirms previous observations(9, 18, 52). This high 357 
variability has intrinsic and extrinsic origins. BA synthesis rate, intestinal absorption and 358 
hepatic processing, as well as bacterial metabolism are just a few factors that may 359 
contribute to the variability. In addition, acute and chronic effects of diet or drug use and 360 
also diurnal variation(14, 18) are known to affect the BA pool. Given the fact that dozens of 361 
proteins are involved in BA synthesis and handling in the mammalian system, it can be 362 
anticipated that there are also numerous underlying genetic factors. Nies et al. attributed 363 
the high inter-individual variability specifically to differences in the expression of 364 
transporters involved in hepatic BA transport such as OATP1B1, OATP1B3 and 365 
OATP2B1(42). Although no systematic study has explored SNPs or haplotypes in relation 366 
to post-prandial plasma BA profiles, a recent study identified epistatic effects in primary BA 367 
biosynthesis by employing an Empirical Bayesian Lasso approach for analysis of pathway-368 
based GWAS data(25).  369 
Based on blood sampling up to 4 (OGTT) or even 8 hours postprandially in the case of 370 
MMTT, distinct kinetic profiles of individual BA species were observed. Maximal increases 371 
in plasma levels exceeding fasting concentrations up to 4.6-fold for taurine- as well as 372 
glycine-conjugated BA were found at 30 min in the OGTT with sustained levels for over 2 373 
hours. These changes match well to those reported previously by others(49),(65). In a study 374 
with 73 young volunteers (26 ± 4 years-old), Matysik et al. demonstrated a rise in glycine- 375 
and taurine-conjugated BA with a peak at 60 minutes after glucose ingestion, although 376 
there was no blood sampling at earlier time points(40). Interestingly, Zhao et. al. reported a 377 
biphasic increase in plasma BA, with the first peak at 30 minutes and a second peak at 120 378 
minutes(65). Although the mean plasma levels in our study did not reveal a biphasic 379 
behavior, some volunteers clearly presented 2 distinct peaks in BA profiles. The fast 380 
appearance of the BA in blood during the OGTT - which in essence can be superimposed 381 
onto the rise in blood glucose levels (Figure 6C and 6F) - suggests a very rapid uptake of 382 
BA in the upper small intestine. Absorption in the duodenum and jejunum is generally not 383 
considered as relevant and is postulated to occur by passive diffusion of protonated BA 384 
species(13, 54). The main site of BA reuptake and delivery into portal circulation is thought 385 
to be the ileum with apical influx via the Na+-dependent SLC10A2 (ASBST) transporter. Our 386 
results however strongly argue for absorption of a considerable quantity of BA already in 387 
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duodenum and jejunum. This applies also for the conjugated BA, since maximal plasma 388 
concentrations were observed here at 30 minutes in response to during the OGTT and at 389 
60 minutes in response to the MMTT, when the majority of ingested nutrients not even have 390 
reached the ileum (Figure 3). 391 
The presence of glucose in the intestinal lumen is known to elicit a cholecystokinin (CCK) 392 
secretion(37) followed by gallbladder contraction. A rise in plasma BA levels in response to  393 
the OGTT is thus per se not surprising. Since BA are not required for glucose absorption, 394 
BA secretion may therefore be taken as an archaic evolutionary response with glucose 395 
sensing as a surrogate for ingested food. CCK secretion is far stronger in response to a 396 
mixed meal and was shown to increase proportional to the lipid content of the meal(37, 50). 397 
Increasing CCK-output translates into differences in gallbladder emptying and 398 
corresponding plasma BA changes(50, 51). Although we did not determine CCK-levels and 399 
gallbladder ejection fraction, it is very reasonable to assume the responses to the OGTT 400 
and MMTT in our volunteers was very similar to those described in other studies44. 401 
Conjugated BA are the most abundant in bile(3, 47) and consequently the post-prandial 402 
plasma changes of these BA as compared to the other species were much more 403 
pronounced. Concentrations of unconjugated BA only mildly increased in a small subset of 404 
subjects after 6 hours in response to the MMTT.  405 
It was previously reported that the increase in plasma levels of conjugated BA in response 406 
to OGTT and oral lipid tolerance tests are higher in women than in men(23, 48), while no 407 
differences are reported in most studies for the fasting state(9, 19, 63). Also in mice, gender 408 
effects in the BA pool were observed and those were related to different expression levels 409 
of BA biosynthetic enzymes(17, 55). Although all women enrolled in our study were post-410 
menopausal, significant differences in post-prandial levels of conjugated BA were still 411 
detectable between men and women, particularly for taurine-conjugated BA during the 412 
OGTT, but also during the MMTT. 413 
Bile acids quantified in systemic circulation are basically the spillover of a non-complete 414 
hepatic extraction of BA in first pass(6, 24). Their concentration in peripheral blood is thus 415 
the result of a series of connected processes with secretion from the gallbladder into 416 
intestine, transit and absorption across apical and basolateral membranes of enterocytes 417 
into portal blood followed by hepatic uptake and biliary secretion. Variability in individual 418 
components within this sequence of events will eventually define the shape of the temporal 419 
plasma BA profile following a meal. We could group our volunteers based on the post-420 
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prandial kinetic profiles into 3 main clusters with different velocities in plasma appearance 421 
and absolute concentrations of BA.  422 
It can be expected that these differences in plasma BA profiles in response to dietary 423 
challenges lead to alterations in physiological processes sensitive to BA. It is known that 424 
GLP-1(22, 27, 56) and insulin(1) secretion as well as substrate oxidation (demonstrated in 425 
rodents) are subject of regulation by BA. And, indeed, we observed an association of post-426 
prandial total plasma BA and GLP-1 concentrations during the OGTT (Figure 8). When 427 
volunteers were clustered according to the increase in plasma levels of glycine-conjugated 428 
BA during the first hour of the OGTT, significant differences between the high and low 429 
responders were observed for circulating GLP-1 levels. This suggests that the rise in GLP-1 430 
initiated by glucose administration may be modulated by BA released into the intestine of by 431 
circulating BA reaching enteroendrocine cells (Figure 8C). The effect was most prominent 432 
for glycine-conjugated BA as the responsive BA category which also has the highest 433 
circulating concentrations. This relationship between BA secretion and corresponding GLP-434 
1 levels was however not observed in the MMTT (Figure 8 D). The MMTT drink also 435 
contained lipids and proteins that can also promote GLP-1 secretion, resulting in a 2-fold 436 
higher plasma GLP-1 and BA levels as compared to the OGTT. Lipids and proteins seem to 437 
promote a stronger GLP-1 output that may overrule the BA modulatory effects on GLP-1 438 
secretion during the MMTT. 439 
One of the most important outcomes of the present study is that genetic variants in the BA 440 
transporter OATP1A2 associate with differences in postprandial BA kinetics but not the 441 
overnight fasting plasma BA levels. Carriers of the nonsynonymous SNP (c.A516C, 442 
p.E172D) in the SLCO1A2 gene displayed significantly lower plasma BA concentrations in 443 
response to the OGTT and during the first hours of the MMTT, indicating reduced and 444 
delayed absorption of BA from intestine. Since OATP1A2 is expressed in the duodenum(4, 445 
20) it is the candidate transporter that could mediate the early phase of BA absorption 446 
leading to rapid changes in plasma BA levels as observed in response to the OGTT in 447 
which peak BA levels can be superimposed on glucose peaks. The A516C variant of 448 
SLCO1A2 was demonstrated to markedly reduce the transport capacity for different 449 
substrates when expressed heterologously(8, 34) although this has not been shown for BA 450 
as substrates. Post-prandial concentrations of unconjugated BA, which are thought to be 451 
taken up into enterocytes via diffusion (not depending on transporters) were not affected in 452 
volunteers with the A516C variant, corroborating the importance of this transporter for 453 
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duodenal BA transport. Although BA concentrations could not be measured in portal blood 454 
in the present study, BA in systemic circulation are considered as a surrogate of 455 
enterohepatic circulation (5), corroborating our hypothesis of a slower intestinal BA uptake 456 
in carriers of the deleterious variation in SLCO1A2. 457 
Taken together, our study describes different BA kinetics following an OGTT and a MMTT 458 
and identified key determinants underlying the large inter-individual variability in 459 
postprandial BA profiles. The different patterns of post-prandial BA responses, associated 460 
with fasting concentrations of BA allowed the classification of the 72 subjects into the 3 461 
major clusters or “metabotypes”. The finding that heterogeneity in 60 preselected genes of 462 
BA synthesis and transport explained most of the BA variance argues for these 463 
metabotypes as mainly genetically determined and not too much dependent on gut 464 
microbiota structure as measured by amplicon sequencing in spite of the known 465 
involvement of specific bacterial species in bile acid metabolism in the intestine. Finally, the 466 
present study is the first to demonstrate an association between a common genetic variant 467 
in the OATP1A2 transporter and post-prandial BA kinetics, despite the absence of any 468 
effects in the fasting state. Understanding the metabolism of BA in the post-prandial state is 469 
essential to better understand their roles in human physiology. 470 
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Figure Legends 705 
 706 
Table 1 – List of selected genes known as involved in BA synthesis and transport that were 707 
screened for deleterious variations. Genes selected represent hormones, membrane 708 
receptors, transcription factors and enzymes involved in BA synthesis as well as 709 
transporters expressed in hepatocytes, bile canaliculi and intestine. 710 
 711 
Table 2 – Effect of different parameters identified by multivariate analyses as responsible 712 
for the observed variation in the most abundant bile acids in plasma in postprandial state. 713 
The numbers in each cell indicate the proportion of variation (in percentage) in each BA 714 
explained by the corresponding variable. The numbers in brackets after gene names 715 
indicate the number of subjects carrying variations in the respective gene. Highlighted cells 716 
indicate significant associations (P<0.05).  717 
 718 
Figure 1 – The energy restriction did not affect BA profiles during OGTT and MMTT 719 
or after a 12-hour fasting. A – Total BA in plasma during the OGTT. B – Total BA in 720 
plasma during the MMTT. Continuous lines represent BA profile before and dotted lines, the 721 
BA profile after a 12 weeks period of intervention with 20% dietary energy restriction. Only 722 
the volunteers that abide to the energy restriction are represented (in control group no 723 
changes due to the energy restriction were observed as well). C – Total BA and BA classes 724 
in plasma after a 12-hour fasting. N = 40. 725 
 726 
Figure 2 – Fasting plasma bile acids. Plasma concentrations of the most abundant BA in 727 
healthy subjects in the overnight fasting state (average of sampling performed at t=0 of 728 
OGTT and MMTT before and after the weight loss intervention). Each differently colored 729 
segment in bars represents the concentration of an individual BA. 730 
 731 
Figure 3 – Plasma BA concentration profiles in response to the OGTT and MMTT. A to 732 
F - Plasma concentrations of different BA classes during the OGTT (dotted line) and MMTT 733 
(full line). G and H – Changes in the composition of the plasma BA pool according to their 734 
conjugation type during the OGTT (G) and MMTT (H). Results are shown as the mean ± 735 
SEM of all volunteers averaging the results of the two challenges performed before and 736 




Figure 4 – Gender effects on plasma BA concentration profiles during the OGTT and 739 
MMTT.  740 
A to C – Plasma concentrations of total, glycine- and taurine-conjugated BA in men (dotted 741 
lines, n=35) and women (full lines, n=37) during the OGTT. D to F – Plasma concentrations 742 
of total, glycine- and taurine-conjugated BA in men (dotted lines, n=35) and women (full 743 
lines, n=37) during the MMTT. Results are shown as the mean ± SEM, averaging the 744 
results of challenges performed before and after intervention. Significant differences in the 745 
AUC after t- test are indicated in the graphs. 746 
 747 
Figure 5 – Clustering of volunteers according to postprandial plasma BA kinetics.  748 
A – Clustering of volunteers based on plasma concentration profiles of bile acids during the 749 
MMTT. B – Changes in total and different classes of bile acids during the MMTT in 750 
participants of the 3 clusters. Results are expressed as mean ± SEM. n=35 in cluster 1, 751 
n=13 in cluster 2 and n=21 in cluster 3. C – Summary of differences found among the 3 752 
clusters for the different bile acid classes as represented in pane B (P≤0.05). 753 
 754 
Figure 6 – Effects of the functional polymorphism A516C in SLCO1A2 (OATP1A2) on 755 
plasma BA kinetics. A to C – Plasma concentrations of bile acids in A516C carriers 756 
(dotted line, n=9) and non-carriers (full line, n=62) during the MMTT. D to F – Plasma 757 
concentrations of bile acids in A516C carriers and non-carriers during the OGTT. Results 758 
are the mean ± SEM of BA levels averaging the results of challenges performed before and 759 
after the weight loss intervention. Statistical differences (multiple T-tests) are indicated in 760 
each graph. The grey area in panes C and F represents the profile of glucose during the 761 
MMTT and OGTT, respectively.  762 
 763 
Figure 7 – De novo clustering analysis of fecal microbiota profiles as obtained by 764 
high-throughput sequencing of 16S rRNA gene amplicons. Partitioning Around 765 
Medoids was performed as described previously. The clustering with best support was 766 
visualized with an NMDS plot (A). Associated changes in alpha-diversity (B) and differential 767 
abundances of taxonomic groups among the clusters (C) were tested statistically in the R 768 
programming environment using Rhea. 769 
 770 
Figure 8 – Relationship between plasma bile acids and GLP-1 concentrations in the 771 
post-prandial state. A and B – Plasma concentrations of glycine-conjugated BA (black 772 
  
 25 
lines) and GLP-1 (grey lines) in response to the OGTT (A) and MMTT (B) (N=72). C and D 773 
– Plasma concentration of glycine-conjugated BA (black lines) and GLP-1 (grey lines). 774 
Subjects were ranked according to post-prandial increase of glycine-conjugated BA 775 
concentrations during the first hour of the OGTT (C) and MMTT (D) (N=36 in each group). 776 






Protein Name Symbol Gene symbol Function
Cholesterol 7α-hydroxylase CYP7A1 CYP7A1 Enzyme 
Sterol 27-hydroxylase CYP27A1 CYP27A1 Enzyme 
25-hydroxycholesterol 7α-hydroxylase CYP7B1 CYP7B1 Enzyme 
24-hydroxycholesterol 7α-hydroxylase CYP39A1 CYP39A1 Enzyme 
Microsomal 3β-hydroxy-Δ5-C27-steroid oxidoreductase HSD3B7 HSD3B7 Enzyme 
Microsomal sterol 12α-hydroxylase CYP8B1 CYP8B1 Enzyme 
Δ4-3-oxosteroid 5β-reductase AKR1D1 AKR1D1 Enzyme 
Acyl-CoA Oxidase 1 ACOX1 ACOX1 Enzyme 
Acyl-CoA Oxidase 2 ACOX2 ACOX2 Enzyme 
Bile Acid-CoA:Amino Acid N-Acyltransferase BAAT BAAT Enzyme 
Bile Acid-CoA Ligase BAL SLC27A5 Enzyme 
α-Methylacyl-CoA Racemase AMACR AMACR Enzyme 
D-bifunctional enzyme DBP DBP Enzyme 
Peroxisomal Thiolase 2 SCP2 SCP2 Enzyme 
Aldo-Keto Reductase Family 1 Member C4 AKR1C4 AKR1C4 Enzyme 
Hydroxysteroid Sulfotransferase HST SULT2A1 Enzyme 
UDP glucuronosyltransferase Family 2 Member B4 UGT2B4 UGT2B4 Enzyme 
UDP glucuronosyltransferase Family 2 Member B7 UGT2B7 UGT2B7 Enzyme 
UDP glucuronosyltransferase Family 1 Member A3 UGT1A3 UGT1A3 Enzyme 
Solute Carrier Family 4 Member 2 SLC4A2 SLC4A2 Enzyme 
Microsomal Epoxide Hydrolase mEH EPHX1 Enzyme 
Cholecystokinin CCK CCK Hormone
Fobroblast Growth Factor 19 FGF19 FGF19 Hormone
Farnesoid X Receptor FXR NR1H4 Nuclear receptor
Small Heterodimer Partner SHP NR0B2 Nuclear receptor
Liver X Receptor LXR NR1H3 Nuclear receptor
Forkhead Box A2 HNF-3β FOXA2 Nuclear receptor
Hepatocyte Nuclear Factor-4α HNF-4α HNF4A Nuclear receptor
G Protein-Coupled Bile Acid Receptor 1 GPBAR1 GPBAR1 Receptor
Bile Salt Export Pump BSEP ABCB11 Transporter
Apical Sodium-dependent BA Transporter ASBT SLC10A2 Transporter
Organic Solute Transporter-α subunit OSTα SLC51A Transporter
Organic Solute Transporter-β subunit OSTβ SLC51B Transporter
Sodium/Taurocholate Cotransporting Polypeptide NTCP SLC10A1 Transporter
Solute Carrier Organic Anion transporter Family Member 1A2 OATP1A2 SLCO1A2 Transporter
Solute Carrier Organic Anion transporter Family Member 1B1 OATP1B1 SLCO1B1 Transporter
Solute Carrier Organic Anion transporter Family Member 1B3 OATP1B3 SLCO1B3 Transporter
Solute Carrier Organic Anion transporter Family Member 2B1 OATP2B1 SLCO2B1 Transporter
ATP Binding Cassette Subfamily C Member 3 ABCC3 ABCC3 Transporter
ATP Binding Cassette Subfamily A Member 1 ABCA1 ABCA1 Transporter
ATP Binding Cassette Subfamily A Member 3 ABCA3 ABCA3 Transporter
ATP Binding Cassette Subfamily G Member 2 ABCG2 ABCG2 Transporter
ATP Binding Cassette Subfamily G Member 5 ABCG5 ABCG5 Transporter
ATP Binding Cassette Subfamily G Member 8 ABCG8 ABCG8 Transporter
ATP Binding Cassette Subfamily C Member 2 ABCC2 ABCC2 Transporter
ATP Binding Cassette Subfamily B Member 1 ABCB1 ABCB1 Transporter
ATP Binding Cassette Subfamily B Member 4 ABCB4 ABCB4 Transporter
ATPase Phospholipid Transporting 8B1 ATP8B1 ATP8B1 Transporter






























































































































































































































































CA 2 1 39 21 0 3 1 5 1 1 3 9 0 0 2 0 2 6 2 1 3 0 0 0 0 0 0 0 5 1 12 2 0 0 0 1 63
CDCA 6 1 38 10 0 2 2 3 0 0 2 4 0 0 0 0 4 6 3 3 8 1 2 0 1 0 0 1 2 0 3 0 0 0 1 0 55
DCA 4 0 54 11 0 0 0 3 0 3 1 6 2 2 2 4 8 2 14 1 1 5 2 1 2 1 0 2 0 1 0 0 1 0 0 1 69
GCA 14 0 23 6 0 1 0 0 3 0 2 1 1 0 1 1 3 1 2 3 4 0 1 0 1 1 0 0 0 0 1 0 0 1 1 0 43
GCDCA 21 1 18 8 0 1 0 0 0 0 2 0 2 0 0 0 3 2 3 0 3 2 1 0 2 1 0 4 0 0 0 0 0 0 0 0 48
GDCA 10 1 50 2 0 0 1 0 1 3 2 2 3 0 3 1 2 0 29 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 63
TCA 5 3 25 4 0 0 3 1 2 1 3 1 0 0 0 1 6 1 0 2 4 0 0 0 0 1 1 0 0 0 0 0 0 2 0 0 37
TCDCA 13 5 24 6 0 0 2 3 1 0 2 2 0 1 0 0 4 2 2 1 2 2 1 0 0 0 1 4 0 0 0 0 0 0 0 0 48
TDCA 7 4 50 3 0 0 0 2 0 1 3 2 2 1 2 1 3 1 31 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 64
0 30 60 90 120 150 180 210 2400246 Time (min)Bile acids (µM) 0 60 120 180 240 300 360 420 4800246810 Time (min)Bile acids (µM)  before interventionafter interventionA B
C















1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72012345678 SubjectsBile acids (µM) CDCACADCAGCDCAGCAGDCAGUDCATCDCATCATDCA taurine-conjugated BAglycine-conjugated BA unconjugated BA
0 60 120 180 240 300 360 420 4800123456 Time (min)Primary bile acids (µM)0 60 120 180 240 300 360 420 4800123456 Time (min)Glycine-conjugated BA (µM) 0 60 120 180 240 300 360 420 48001234 Time (min)Secondary + tertiary  BA (µM)0 60 120 180 240 300 360 420 4800.00.20.40.60.81.01.21.4 Time (min)Taurine-conjugated BA (µM) 0 60 120 180 240 300 360 420 4800.00.51.01.52.02.5 Time (min)Non-conjugated BA (µM)0 60 120 180 240 300 360 420 4800246810 Time (min)Bile acids (µM) MMTTOGTTAD 0 15 30 60 90 120 240020406080100 Time (min)BA composition (%) 47 63 62 61 55605346 27 29 30 3629368 10 10 9 91110 0 30 60 120 240 360 480020406080100 Time (min)BA composition (%) 47 68 66 65 58676046 20 23 24 3322277 10 11 10 91112G H CB FE non-conjugated BAglycine-conjugated BAtaurine-conjugated BA
0 30 60 90 120 150 180 210 24012345 Time (min)Bile acids (µM) womenmenP=0.0010 60 120 180 240 300 360 420 4800246810 Time (min)Bile acids (µM) 0 30 60 90 120 150 180 210 24001234 Time (min)Glycine conj. BA (µM) 0 60 120 180 240 300 360 420 48002468 Time (min)Glycine conj. BA (µM) 0 30 60 90 120 150 180 210 2400.00.20.40.6 Time (min)Taurine conj. BA (µM) 0 60 120 180 240 300 360 420 4800.00.20.40.60.81.01.2 Time (min)Taurine conj. BA (µM)A B CD E FP = 0.0098 for AUC difference P < 0.0001 for AUC differenceP = 0.0085 for AUC difference
0 60 120 180 240 300 360 420 4800.03.06.09.012.0 Time (min)Bile acids (µM) cluster 3cluster 2cluster 1 0 60 120 180 240 300 360 420 4800.01.02.03.04.0 Time (min)Unconjugated bile acids (µM) 0 60 120 180 240 300 360 420 4800.02.04.06.08.0 Time (min)Glycine conjugated BA (µM)0 60 120 180 240 300 360 420 4800.00.51.01.5 Time (min)Taurine-conj. BA (µM)B
C
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0 30 60 90 120 150 180 210 2400.00.51.01.52.02.5 Time (min)Unconjugated BA (µM) 0 30 60 90 120 150 180 210 2400123456 1.01.52.0Time (min)Glycine-conj. BA (nM) * * 0 30 60 90 120 150 180 210 2400.00.20.40.60.81.0 0.81.01.21.41.6Time (min)Taurine-conj. BA (nM) * Glucose (FC)0 60 120 180 240 300 360 420 4800.00.51.01.52.02.5 Time (min)Unconjugated BA (µM) non-carriersc.A516C carriers 0 60 120 180 240 300 360 420 4800123456 0.91.01.11.21.3Time (min)Glycine-conj. BA (nM) * * 0 60 120 180 240 300 360 420 4800.00.20.40.60.81.0 0.81.01.21.41.6Time (min)Taurine-conj. BA (nM) * Glucose (FC)A B CD E F







































































































GLP-1 in subjects with low post-prandial BA increase
GLP-1 in subjects with high post-prandial BA increase
BA in subjects with low post-prandial BA increase
BA in subjects with high post-prandial BA increase
P = 0.007 for GLP-1 AUC difference 
